Skip to main content

Advertisement

SpringerLink
Log in

The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: Where do we stand?

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Iron overload (IO), primarily related to multiple red blood cell transfusions, is a relatively common complication in hematopoietic stem cell transplant (HSCT) recipients. Elevated pretransplant ferritin levels have been reported to increase the risk of non-relapse mortality following HSCT and might influence the risk of acute and chronic graft versus host disease. IO has been shown to be an important cause of mortality and morbidity in patients who have undergone alloHSCT (Armand et al., Blood 109:4586–4588, 2007; Kim et al., Acta Haematol 120:182–189, 2008; Kataoka et al., Biol Blood Marrow Transplant 15:195–204, 2009). We know that excessive iron accumulation results in tissue damage and organ failure, mainly as a result of the generation of free radicals that cause oxidative damage and organ dysfunction (e.g., hepatotoxicity, cardiotoxicity, and endocrine dysfunction) (Altes et al., Bone Marrow Transplantation 29: 987–989, 2002; Papanikolaou et al., Toxicol Appl Pharmac 202:199–211, 2005). In the last decade, efforts have been directed toward identifying alternative treatment for IO in alloHSCT recipients to maintain improved transplant outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Strasser SI, Kowdley KV, Sale GE, McDonald GB (1998) Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 22:167–173

    Article  PubMed  CAS  Google Scholar 

  2. Butt NM, Clark RE (2003) Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia. Bone Marrow Transplant 32:909–913

    Article  PubMed  CAS  Google Scholar 

  3. Kataoka K, Nannya Y, Hangaishi A, Imai Y, Chiba S, Takahashi T, Kurokawa M (2009) Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15:195–204

    Google Scholar 

  4. Altes A, Remacha AF, Sureda MR, Briones J, Canals C, Brunet S, Sierra J, Gimferrer E (2002) Iron overload might increase transplant-related mortality in haemotopoietic stem cell transplantation. Bone Marrow Transplant 29:987–989

    Google Scholar 

  5. Papanikolaou G, Pantopoulos K (2005) Iron metabolism and toxicity. Toxicol Appl Pharmacol 202:199–211

    Google Scholar 

  6. Armand P, Kim HT, Cutler CS,Ho VT, Koreth J, Alyea EP, Soiffer RJ, Antin JH (2007) Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109:4586–8

    Google Scholar 

  7. Kim YR, Kim JS, Cheong JW, Song JW, Min YH (2008) Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies. Acta Haematol 120:182–9

    Google Scholar 

  8. Kamble RT, Selby GB, Mims M, Kharfan-Dabaja MA, Ozer H,George JN (2006) Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12:506–510

    Google Scholar 

  9. Majhail NS, Lazarus HM, Burns LJ (2008) Iron overload in hematopoietic cell transplantation. BoneMarrow Transplant 41:997–1003

    Google Scholar 

  10. Evens AM, Mehta J, Gordon LI (2004) Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant 34:561–571

    Google Scholar 

  11. Maertens J, Demuynck H, Verbeken EK, Zachée P, Verhoef GE, Vandenberghe P, Boogaerts MA (1999) Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 24:307–312

    Article  PubMed  CAS  Google Scholar 

  12. Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F, Barlogie B, Anaissie EJ (2006) Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 37:857–864

    Article  PubMed  CAS  Google Scholar 

  13. Gaziev J, Lucarelli G (2011) Hematopoietic stem cell transplantation for thalassemia. Curr Stem Cell Res Ther 6:162–169

    Article  PubMed  CAS  Google Scholar 

  14. Sivgin S, Baldane S, Kaynar L, Kurnaz F, Pala C, Sivgin H, Ozturk A, Cetin M, Unal A, Eser B (2012) Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation. Neoplasma 59:183–190

    Article  PubMed  CAS  Google Scholar 

  15. Mahindra A, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Kalaycio M, Sweetenham J, Bolwell B, Copelan E (2009) Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation. Bone Marrow Transplant 44:767–768

    Article  PubMed  CAS  Google Scholar 

  16. Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Weetenham J, Kalaycio M, Copelan E (2009) Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 146:310–6

    Google Scholar 

  17. Carpenter CE, Mahoney AW (1992) Contributions of heme and non-heme iron to human nutritions. Crit Rev Food Sci Nutr 31:333–367

    Article  PubMed  CAS  Google Scholar 

  18. Gordon LI, Brown SG, Tallman MS, Rademaker AW, Weitzman SA, Lazarus HM, Kelley CH, Mangan C, Rubin H, Fox RM (1995) Sequential changes in serum iron and ferritin in patients undergoing high dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicity. Free Rad Biol Med 18:383–389

    Article  PubMed  CAS  Google Scholar 

  19. Lipschitz DA, Cook JD, Finch CA (1974) A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 290:1213–1216

    Article  PubMed  CAS  Google Scholar 

  20. Cazzola M, Della Porta MG, Malcovati L (2008) Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematol Am Soc Hematol Educ Prog 2008:166–175

    Article  Google Scholar 

  21. Finch CA, Huebers H (1982) Perspectives in iron metabolism. N Engl J Med 306:1520–1528

    Article  PubMed  CAS  Google Scholar 

  22. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ, Thalassemia International Federation Heart T2* Investigators (2006) Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 91(10):1388–1391

    PubMed  CAS  Google Scholar 

  23. McKay PJ, Murphy JA, Cameron S, Burnett AK, Campbell M, Tansey P, Franklin IM (1996) Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 17:63–66

    PubMed  CAS  Google Scholar 

  24. Tomas JF, Pinilla I, Garcia-Buey ML, García A, Figuera A, Gómez-García de Soria VGG, Moreno R, Fernández-Rañada JM (2000) Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant 26:649–655

    Article  PubMed  CAS  Google Scholar 

  25. Sucak GT, Yegin ZA, Ozkurt ZN, Aki SZ, Karakan T, Akyol G (2008) The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated? Bone Marrow Transplant 42:461–467

    Article  PubMed  CAS  Google Scholar 

  26. Ho GT, Parker A, MacKenzie JF, Morris AJ, Stanley AJ (2004) Abnormal liver function tests following bone marrow transplantation: aetiology and role of liver biopsy. Eur J Gastroenterol Hepatol 16:157–162

    Article  PubMed  Google Scholar 

  27. Ali S, Pimentel JD, Munoz J, Shah V, McKinnon R, Divine G, Janakiraman N (2012) Iron overload in allogeneic hematopoietic stem cell transplant recipients. Arch Pathol Lab Med 136:532–538

    Article  PubMed  CAS  Google Scholar 

  28. Emond MJ, Bronner MP, Carlson TH, Lin M, Labbe RF, Kowdley KV (1999) Quantitative study of the variability of hepatic iron concentrations. Clin Chem 45:340–346

    PubMed  CAS  Google Scholar 

  29. Sheth S (2003) SQUID biosusceptometry in the measurement of hepatic iron. Pediatr Radiol 33:373–377

    PubMed  Google Scholar 

  30. Dunscombe PB, Katz DE, Stacey AJ (1984) Some practical aspects of dual-energy CT scanning. Br J Radiol 57:82–87

    Article  PubMed  CAS  Google Scholar 

  31. Hazirolan T, Akpinar B, Unal S, Gümrük F, Haliloglu M, Alibek S (2008) Value of dual energy computed tomography for detection of myocardial iron deposition in thalassaemia patients: initial experience. Eur J Radiol 68:442–445

    Article  PubMed  Google Scholar 

  32. Yeh BM, Shepherd JA, Wang ZJ, Teh HS, Hartman RP, Prevrhal S (2009) Dual-energy and low-kVp CT in the abdomen. Am J Roentgenol 193:47–54

    Article  Google Scholar 

  33. Wood JC (2007) Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 14:183–190

    Article  PubMed  Google Scholar 

  34. Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Sweetenham J, Kalaycio M, Copelan E (2008) Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transplant 14:1239–1244

    Article  PubMed  Google Scholar 

  35. Petrikkos G, Drogari-Apiranthitou M (2011) Zygomycosis in ımmunocompromised non-haematological patients. Mediterr J Hematol Infect Dis 3:2011–2012

    Google Scholar 

  36. Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott BL, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorror ML, Ehninger G, Deeg HJ (2008) Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Bone Marrow Transplant 14:1217–1225

    Article  CAS  Google Scholar 

  37. Morado M, Ojeda E, Garcia-Bustos J, Aguado MJ, Arrieta R, Quevedo E, Navas A, Hernandez-Navarro F (2000) BMT: serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study. Hematology 4:505–512

    PubMed  CAS  Google Scholar 

  38. Maradei SC, Maiolino A, de Azevedo AM, Colares M, Bouzas LF, Nucci M (2009) Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 6(114):1270–1275

    Article  Google Scholar 

  39. Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J, Forman SJ (2008) Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 42:799–805

    Article  PubMed  CAS  Google Scholar 

  40. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, Manning JT, Han X (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110:1303–1306

    Article  PubMed  Google Scholar 

  41. Poutsiaka DD, Price LL, Ucuzian A, Chan GW, Miller KB, Snydman DR (2007) Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant 40:63–70

    Article  PubMed  CAS  Google Scholar 

  42. Gaziev J, Sodani P, Polchi P, Andreani M, Lucarelli G (2005) Bone marrow transplantation in adults with thalassemia treatment and long-term follow-up. Ann NY Acad Sci 1054:196–205

    Article  PubMed  Google Scholar 

  43. Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G (1995) Intravenous chelation therapy during transplantation for thalassemia. Haematologica 80:300–304

    PubMed  CAS  Google Scholar 

  44. Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, Falda M, Onida F, Bernardi M, Guidi S, Lucarelli B, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Pascutto C, Oneto R, Pirolini L, Fanin R, Bosi A (2010) Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 95:476–484

    Article  PubMed  CAS  Google Scholar 

  45. Hunter RL, Bennett B, Towns M, Vogler WR (1984) Transferrin in disease II: defects in the regulation of transferrin saturation with iron contribute to susceptibility to infection. Am J Clin Pathol 81:748–853

    PubMed  CAS  Google Scholar 

  46. Blei F, Puder DR (1993) Yersinia enterocolitica bacteremia in a chronically transfused patient with sickle cell anemia. Case report and review of the literature. Am J Pediatr Hematol Oncol 15:430–434

    PubMed  CAS  Google Scholar 

  47. Lee AC, Ha SY, Yuen KY, Lau YL (1995) Listeria septicemia complicating bone marrow transplantation for Diamond–Blackfan syndrome. Pediatr Hematol Oncol 12:295–299

    Article  PubMed  CAS  Google Scholar 

  48. Bonsdorff VL, Sahlstedt L, Ebeling F, Ruutu T, Parkkinen J (2003) Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. FEMS Immunol Med Microbiol 37:45–51

    Article  Google Scholar 

  49. Sivgin S, Eser B, Bahcebasi S, Kaynar L, Kurnaz F, Uzer E, Pala C, Deniz K, Ozturk A, Cetin M, Unal A (2012) Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT). Ann Hematol 91:743–749

    Article  PubMed  CAS  Google Scholar 

  50. Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276:7806–7810

    Article  PubMed  CAS  Google Scholar 

  51. Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26:323–342

    Article  PubMed  CAS  Google Scholar 

  52. Kanda J, Uchiyama T, Tomosugi N, Higuchi M, Uchiyama T, Kawabata H (2009) Oncostatin M and leukemia inhibitory factor increase hepcidin expression in hepatoma cell lines. Int J Hematol 90:545–552

    Article  PubMed  CAS  Google Scholar 

  53. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–2093

    Article  PubMed  CAS  Google Scholar 

  54. Preza GC, Ruchala P, Nemeth E, Ganz T (2010) Minihepcidins: small peptides involved in disulfide exchange with ferroportin act as agonists. FASEB J 24:1011

    Google Scholar 

  55. Corradini E, Schmidt PJ, Meynard D, Garuti C, Montosi G, Chen S, Vukicevic S, Pietrangelo A, Lin HY, Babitt JL (2010) BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology 139:1721–1729

    Article  PubMed  CAS  Google Scholar 

  56. Ganz T, Nemeth E (2011) The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011:538–542

    Article  PubMed  Google Scholar 

  57. Preza GC, Ruchala P, Pinon R, Ramos E, Qiao B, Peralta MA, Sharma S, Waring A, Ganz T, Nemeth E (2011) Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest 121:4880–4888

    Article  PubMed  CAS  Google Scholar 

  58. Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E, Ganz T (2012) Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 120(18):3829–3836

    Article  PubMed  CAS  Google Scholar 

  59. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G (2010) Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation- induced anemia. Blood 115:3616–3624

    Article  PubMed  CAS  Google Scholar 

  60. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY (2007) Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117:1933–1939

    Article  PubMed  CAS  Google Scholar 

  61. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J, UK MDS Guidelines Group (2003) Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120:187–200

    Article  PubMed  Google Scholar 

  62. Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S, Italian Society of Hematology (2010) Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 34:1576–1588

    Article  PubMed  CAS  Google Scholar 

  63. Alessandrino EP, Angelucci E, Cazzola M, Della Porta MG, Di Bartolomeo P, Gozzini A, Malcovati L, Pioltelli P, Simona Sica S, Bosi A (2011) Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo. Am J Hematol 86:897–902

    Article  PubMed  Google Scholar 

  64. Busca A, Falda M, Manzini P, D’Antico S, Valfrè A, Locatelli F, Calabrese R, Chiappella A, D’Ardia S, Longo F, Piga A (2010) Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transplant 16:115–122

    Article  PubMed  CAS  Google Scholar 

  65. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, Davies SM, Ferrara JL, Socié G (2006) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 12:138–151

    Article  PubMed  Google Scholar 

  66. Angelucci E, Muretto P, Lucarelli G, Ripalti M, Baronciani D, Erer B, Galimberti M, Giardini C, Gaziev D, Polchi P (1997) Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 90:994–998

    PubMed  CAS  Google Scholar 

  67. Olivieri NF, Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89:739–761

    PubMed  CAS  Google Scholar 

  68. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Séchaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo- controlled, dose-escalation trial. Lancet 361:1597–1602

    Article  PubMed  CAS  Google Scholar 

  69. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89:1187–1193

    PubMed  Google Scholar 

  70. Fu D, Richardson DR (2007) Iron chelation and regulation of the cell cycle:2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 110:752–761

    Article  PubMed  CAS  Google Scholar 

  71. Nurtjahja-Tjendraputra E, Fu D, Phang JM, Richardson DR (2007) Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood 109:4045–4054

    Article  PubMed  CAS  Google Scholar 

  72. Hider RC, Zhou T (2005) The design of orally active iron chelators. Ann N Y Acad Sci 1054:141–154

    Article  PubMed  CAS  Google Scholar 

  73. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefàno I, Tricta F (2002) The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 118:330–336

    Article  PubMed  CAS  Google Scholar 

  74. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F (2003) Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102:1583–1587

    Article  PubMed  CAS  Google Scholar 

  75. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 107:3455–3462

    Article  PubMed  CAS  Google Scholar 

  76. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwiatkowski J, Quarta G, Jeng M, Forni GL, Stadler M, Cario H, Debusscher L, Della Porta M, Cazzola M, Greenberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective study. Eur J Haematol 80:168–176

    PubMed  CAS  Google Scholar 

  77. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T (2007) A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136:501–508

    Article  PubMed  CAS  Google Scholar 

  78. Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr, Spellberg BJ (2007) The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 117:2649–2657

    Article  PubMed  CAS  Google Scholar 

  79. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, Follenzi A, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S (2010) Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. Clin Invest 120:4466–4477

    Article  CAS  Google Scholar 

  80. Rienhoff HY Jr, Viprakasit V, Tay L, Harmatz P, Vichinsky E, Chirnomas D, Kwiatkowski JL, Tapper A, Kramer W, Porter JB, Neufeld EJ (2011) A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica 96:521–525

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The author reports no conflicts of interest in this work.

Author information

Authors and Affiliations

  1. Department of Hematology, Faculty of Medicine, Dedeman Stem Cell Transplantation Hospital, Erciyes University, Kayseri, Turkey

    Serdar Sivgin & Bulent Eser

Authors
  1. Serdar Sivgin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bulent Eser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Serdar Sivgin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sivgin, S., Eser, B. The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: Where do we stand?. Ann Hematol 92, 577–586 (2013). https://doi.org/10.1007/s00277-013-1682-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1682-8

Keywords

Search

Navigation